Table 2 Baseline characteristics of included patients from the FINNAKI cohort
From: Burden of acute kidney injury and 90-day mortality in critically ill patients
Data available | Survivors N = 2156 | Data available | Non-survivors N = 653 | |
|---|---|---|---|---|
Age, years (SD) | 2156 | 58.9 (16.8) | 653 | 67.9 (14.0) |
Gender, male (%) | 2156 | 1368 (63.5) | 653 | 424 (64.9) |
BMI, kg/m2 (SD) | 2137 | 29.1 (27.7) | 647 | 27.9 (16.5) |
Baseline creatinine, mmol/L (IQR) | 1340 | 74 (60–90) | 450 | 78 (63–103) |
Co-morbidities | ||||
Hypertension, n (%) | 2143 | 979 (45.7) | 650 | 350 (53.8) |
Diabetes mellitus, n (%) | 2156 | 470 (21.8) | 653 | 137 (21.0) |
COPD, n (%) | 2142 | 180 (8.4) | 650 | 73 (11.2) |
Systolic heart failure, n (%) | 2138 | 213 (10.0) | 647 | 109 (16.8) |
Chronic liver failure, n (%) | 2136 | 60 (2.8) | 643 | 49 (7.6) |
Chronic renal failure*, n (%) | 2147 | 118 (5.5) | 650 | 63 (9.7) |
Pre-ICU daily medication | ||||
Diuretic, n (%) | 2125 | 550 (25.9) | 634 | 229 (36.1) |
Statin, n (%) | 2127 | 633 (29.8) | 639 | 195 (30.5) |
Metformin, n (%) | 2125 | 270 (12.7) | 639 | 65 (10.2) |
NSAID, n (%) | 2080 | 190 (9.1) | 618 | 51 (8.3) |
Corticosteroid, n (%) | 2132 | 118 (5.5) | 642 | 96 (15.0) |
Admission | ||||
Emergency, n (%) | 2156 | 1828 (85.9) | 653 | 623 (95.7) |
Operative, n (%) | 2156 | 824 (38.2) | 653 | 164 (25.1) |
Mechanical ventilation, n (%) | 2156 | 1404 (65.1) | 653 | 531 (81.3) |
Vasopressor use, n (%) | 2156 | 1212 (56.2) | 653 | 461 (70.6) |
SAPS II (SD) | 2156 | 35.2 (14.0) | 653 | 54.4 (18.2) |
SOFA score (SD) | 2156 | 6.4 (3.1) | 653 | 9.6 (3.9) |